Nuformix PLC Appointment of Broker (1048Y)
01 December 2017 - 6:30PM
UK Regulatory
TIDMNFX
RNS Number : 1048Y
Nuformix PLC
01 December 2017
Nuformix plc
("Nuformix" or "the Company")
Appointment of Broker
Nuformix, the pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs, is pleased to announce the appointment of Beaufort
Securities Limited as the Company's broker.
Follow Nuformix on Vox Markets: follow at
www.voxmarkets.co.uk/company/NFX
and www.nuformix.com
ENDS
Enquiries:
Nuformix plc
Dan Gooding, Chief
Executive Officer +44 (0)1223 423667
Beaufort Securities
Limited (Joint
Broker) +44 (0)20 7382
Jon Belliss 8300
Gable Communications
Ltd
John Bick / Justine +44 (0)20 7193
James 7463
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix' risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix has created an IP portfolio containing a range of
granted patents covering cocrystal forms of five small molecule
drugs. Nuformix is targeting high-value unmet needs with its lead
programmes in oncology supportive care: NXP001 and fibrosis:
NXP002.
Nuformix was established in Cambridge in 2008 and has invested
into pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities. Nuformix plc shares are
traded on the London Stock Exchange's Official List under the
ticker: NFX.L.
This information is provided by RNS
The company news service from the London Stock Exchange
END
APPFSWSWFFWSEEE
(END) Dow Jones Newswires
December 01, 2017 02:30 ET (07:30 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2024 to May 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From May 2023 to May 2024
